Forte Biosciences Inc. (FBRX)
NASDAQ:FBRX
Total Valuation
Forte Biosciences has a market cap or net worth of $355.20M. The enterprise value is $243.48M.
Market Cap$355.20M
Enterprise Value$243.48M
Share Statistics
Forte Biosciences has 13,885,668 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,885,668
Owned by Insiders2.97%
Owned by Institutions46.64%
Financial Efficiency
Forte Biosciences’s return on equity (ROE) is -1.14 and return on invested capital (ROIC) is -113.91%.
Return on Equity (ROE)-1.14
Return on Assets (ROA)-0.84
Return on Invested Capital (ROIC)-113.91%
Return on Capital Employed (ROCE)-1.14
Revenue Per Employee0.00
Profits Per Employee-4.96M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Forte Biosciences is ―. Forte Biosciences’s PEG ratio is 0.94.
PE Ratio―
PS Ratio0.00
PB Ratio65.81
Price to Fair Value65.81
Price to FCF-78.70
Price to Operating Cash Flow-73.99
PEG Ratio0.94
Income Statement
In the last 12 months, Forte Biosciences had revenue of 0.00 and earned -69.38M in profits. Earnings per share was -4.71.
Revenue0.00
Gross Profit0.00
Operating Income-70.66M
Pretax Income-68.34M
Net Income-69.38M
EBITDA-70.66M
Earnings Per Share (EPS)-4.71
Cash Flow
In the last 12 months, operating cash flow was -50.88M and capital expenditures -116.00K, giving a free cash flow of -51.00M billion.
Operating Cash Flow-50.88M
Free Cash Flow-51.00M
Free Cash Flow per Share-3.67
Dividends & Yields
Forte Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change335.03%
50-Day Moving Average28.83
200-Day Moving Average18.90
Relative Strength Index (RSI)44.46
Average Volume (3m)97.46K
Important Dates
Forte Biosciences upcoming earnings date is May 18, 2026, After Close (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Forte Biosciences as a current ratio of 3.88, with Debt / Equity ratio of 0.00%
Current Ratio3.88
Quick Ratio3.88
Debt to Market Cap0.00
Net Debt to EBITDA1.09
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Forte Biosciences has paid 1.04M in taxes.
Income Tax1.04M
Effective Tax Rate-0.02
Enterprise Valuation
Forte Biosciences EV to EBITDA ratio is -55.71, with an EV/FCF ratio of -77.19.
EV to Sales0.00
EV to EBITDA-55.71
EV to Free Cash Flow-77.19
EV to Operating Cash Flow-77.37
Balance Sheet
Forte Biosciences has $76.96M in cash and marketable securities with $0.00 in debt, giving a net cash position of $76.96M billion.
Cash & Marketable Securities$76.96M
Total Debt$0.00
Net Cash$76.96M
Net Cash Per Share$5.54
Tangible Book Value Per Share$0.41
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Forte Biosciences is $75.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$75.00
Price Target Upside193.20% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast77.08%